Palvella Therapeutics (NasdaqCM:PVLA) Update / Briefing Transcript
2025-11-05 14:30
Palvella Therapeutics (NasdaqCM:PVLA) Update / Briefing November 05, 2025 08:30 AM ET Speaker1Stones. Moving left to right, number one, we are charging towards the clinic with our Qtorin Rapamycin for clinically significant angiokeratomas program, our third clinical indication for Qtorin Rapamycin. Number two, today we achieve our second of four milestones with the announcement of our next Qtorin platform program, Qtorin Pitavastatin for the treatment of disseminated superficial actinic porokeratosis. As no ...